Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results
Key clinical point: Relative to whole-breast irradiation, APBI using 3D-CRT has slightly poorer long-term cosmetic and toxicity outcomes.
Major finding: At 5 years, the APBI group had higher rates of late grade 3 or 4 bone toxicity (1.0% vs. 0%; P < .05) and soft tissue toxicity (2.6% vs. 1.1%; P < .05).
Study details: A multicenter phase 3 randomized controlled trial among 3,279 women with early-stage breast cancer treated with breast-conserving surgery (IRMA trial).
Disclosures: Dr. Meduri disclosed expert board service for MSD, and financial support for attending congresses from Ipsen, AstraZeneca, and Merck. The trial was sponsored by Regione Emilia-Romagna. Dr. Shah disclosed consulting for ImpediMed and PreludeDX, and receiving grants from Varian, VisionRT, and PreludeDX.
Meduri B et al. ESTRO 2020. Abstract 611.